Author/Authors :
Sahinarslan, Asife Department of Cardiology - Faculty of Medicine - Gazi University - Ankara - Turkey , Gazi, Emine Department of Cardiology - Faculty of Medicine - 18 Mart University - Çanakkale - Turkey , Aktoz, Meryem Department of Cardiology - Faculty of Medicine - Trakya University - Edirne - Turkey , Ozkan, Cigdem Department of Endocrinology - İzmir Bozyaka Training and Research Hospital - İzmir - Turkey , Ulusal Okyay, Gülay Department of Nephrology - Health Sciences University - Dışkapı Yıldırım Beyazıt Training and Research Hospital - Ankara - Turkey , Elalmis, Ozgul Ucar Department of Cardiology - Ankara City Hospital - Ankara - Turke , Belen, Erdal Department of Cardiology - İstanbul Okmeydanı State Hospital - İstanbul - Turkey , Bitigen, Atila Department of Cardiology - Fatih Medical Park Hospital - İstanbul - Turkey , Derici, Ulver Department of Nephrology - Faculty of Medicine - Gazi University - Ankara - Turkey , Bascil Tutuncu, Neslihan Department of Endocrinology - Faculty of Medicine - Başkent University - Ankara - Turkey , Yildirir, Aylin Department of Cardiology - Faculty of Medicine - Başkent University - Ankara - Turkey
Abstract :
Hypertension is one of the major cardiovascular risk factors,
closely related to the major cardiovascular, neurological, and
renal adverse events (1, 2). Resistant hypertension (RHT), characterized by uncontrolled blood pressure (BP) despite intensive
treatment, was shown to have 3 times more cardiovascular risk
compared with controlled BP (3, 4). Moreover, this higher risk is
not limited only to cardiovascular events, but also to end-organ
damage. It is well documented that effective control of high BP
in patients with RHT provides a significant decrease in major adverse events including cardiovascular and renal problems (5, 6)
